Medium impact
Provider Criteria Change
Arkansas Blue Cross Blue Shield·Effective Nov 11, 2026
Arkansas Blue Cross updated coverage criteria for three medication policies effective November 11, 2026: (1) Paliperidone palmitate long-acting injectables now include new 6-month formulation (Invega Hafyera) with added authorization renewal criteria for all formulations; (2) Teplizumab-mzwv (Tzield) expanded to newest FDA-approved label covering Stage 2 Type 1 Diabetes in patients 1+ years old; (3) Immune Globulin policies reformatted for InterQual customization. Billing teams must update prior authorization requirements and clinical criteria validation processes.